New preprint: Deciphering bedaquiline and clofazimine resistance in tuberculosis Philip Fowler, 22nd March 202122nd March 2021 0 shares In this preprint we examine 14,151 clinical isolates drawn from the CRyPTIC dataset. Each isolate had its minimum inhibitory concentration (MIC) to bedaquiline and clofazimine measured and hence we were able to identify the transcription regulator Rv0678, as the current main source of elevated MICs to both these drugs. Lindsay Sonnenkalb, who is studying for her PhD with Stefan Niemann, then evolved Mycobacterium tuberculosis strains under sub-lethal concentrations of both compounds and was able to identify 189 different Rv0678 genetic variants that confer elevated MICs to bedaquiline and clofazimine. Detailed modelling of the protein structure allowed us to posit four main resistance mechanisms: impairment of DNA binding, reduction in protein stability, disruption of protein dimerization, and reduction in affinity for its fatty acid ligand. Share this:Twitter Related antimicrobial resistance clinical microbiology publication
publication New Publication: NRas slows the rate at which a model lipid bilayer phase separates 13th June 2014 Here we examine by computer simulation what effect adding a small cell-signalling protein does… Share this:Twitter Read More
Viki Brunner wins poster prize 23rd November 202223rd November 2022 The whole group attended the first INEOS Oxford Institute meeting on Multidisciplinary Approaches to AMR… Share this:Twitter Read More
clinical microbiology Our World in Data 10th January 202410th January 2024 I didn’t know that Our World in Data was also based at the University of… Share this:Twitter Read More